Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,15 USD | -2,54% | 0,00% | -35,39% |
Omzet 2024 * | 74,06 mln. 69,27 mln. | Omzet 2025 * | 127 mln. 119 mln. | Marktkapitalisatie | 84,01 mln. 78,57 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 17 mln. 15,9 mln. | Nettowinst (verlies) 2025 * | 70 mln. 65,47 mln. | EV/omzet 2024 * | 1,13 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,66 x |
K/w-verhouding 2024 * |
5,48
x | K/w-verhouding 2025 * |
1,42
x | Werknemers | 208 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,23% |
Recentste transcriptie over Protalix BioTherapeutics, Inc.
1 dag | -2,54% | ||
Lopende maand | -8,73% | ||
1 maand | -8,00% | ||
3 maanden | -22,30% | ||
6 maanden | -19,58% | ||
Lopend jaar | -35,39% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30-06-19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22-07-19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01-12-19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01-12-19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01-11-14 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 34 M€ | +2,14% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,15 | -2,54% | 958 735 |
25-04-24 | 1,18 | -2,48% | 192 155 |
24-04-24 | 1,21 | +0,83% | 228 353 |
23-04-24 | 1,2 | +1,69% | 272 095 |
22-04-24 | 1,18 | +2,61% | 225 065 |
uitgestelde koers Nyse, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-35,39% | 84,01 mln. | |
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |